---
trial_id: 482
discovery_date: 2022-04-05 21:16:14.458656
date: 2022-04-05 21:16:14.458656
title: "Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis"
summary: |
  <p>EudraCT Number: 2021-000048-23<br />Sponsor Protocol Number: P2-IMU-838-PMS<br />Sponsor Name: Immunic AG<br />Start Date: 2021-10-28<br />Medical condition: Progressive forms of Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/NL">NL</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000048-23'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2021-000048-23<br />Sponsor Protocol Number: P2-IMU-838-PMS<br />Sponsor Name: Immunic AG<br />Start Date: 2021-10-28<br />Medical condition: Progressive forms of Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/NL">NL</a> (Ongoing)</p>